At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
In Brief
A Phase 3 clinical trial evaluating Docetaxel, Laboratory Biomarker Analysis, and 1 other intervention for CCND1 Gene Amplification and 5 related conditions. Completed, enrolled 53 participants across 1,065 sites.
Detailed Summary
This phase II/III trial studies how well palbociclib works in treating cell cycle gene alteration positive patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for cell cycle gene alterations which can cause tumor cells to grow more quickly. Palbociclib may slow cell cycle progression and may be able to shrink tumors.
Study Details
Timeline
Interventions
Given IV (arm II closed to accrual 12/18/2015)
Correlative studies
Given PO